These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 36878753)

  • 1. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
    Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
    Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
    Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
    Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
    De Bruycker A; Spiessens A; Dirix P; Koutsouvelis N; Semac I; Liefhooghe N; Gomez-Iturriaga A; Everaerts W; Otte F; Papachristofilou A; Scorsetti M; Shelan M; Siva S; Ameye F; Guckenberger M; Heikkilä R; Putora PM; Zapatero A; Conde-Moreno A; Couñago F; Vanhoutte F; Goetghebeur E; Reynders D; Zilli T; Ost P
    BMC Cancer; 2020 May; 20(1):406. PubMed ID: 32398040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
    Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience.
    Boeri L; Sharma V; Kwon E; Stish BJ; Davis BJ; Karnes RJ
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):514-523. PubMed ID: 33268854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.
    Bravi CA; Droghetti M; Fossati N; Gandaglia G; Suardi N; Mazzone E; Cucchiara V; Scuderi S; Barletta F; Schiavina R; Osmonov D; Juenemann KP; Boeri L; Karnes RJ; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Grubmüller B; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol Oncol; 2022 Jun; 5(3):285-295. PubMed ID: 34176768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
    Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
    Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
    Rans K; Charlien B; Filip A; Olivier H; Julie DH; Céderic D; Herlinde D; Benedikt E; Karolien G; Annouschka L; Nick L; Kenneth P; Carl S; Koen S; Hans V; Ben V; Steven J; Gert M
    BMC Cancer; 2022 Dec; 22(1):1294. PubMed ID: 36503429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
    Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
    Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
    Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.
    Bianchi L; Ceci F; Balestrazzi E; Costa F; Droghetti M; Piazza P; Pissavini A; Presutti M; Farolfi A; Mei R; Castellucci P; Gandaglia G; Larcher A; Robesti D; Mottrie A; Briganti A; Morganti AG; Fanti S; Montorsi F; Schiavina R; Brunocilla E
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy.
    Devos G; Berghen C; Van Eecke H; Stichele AV; Van Poppel H; Goffin K; Mai C; De Wever L; Albersen M; Everaerts W; De Meerleer G; Joniau S
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32823690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.
    Fossati N; Suardi N; Gandaglia G; Bravi CA; Soligo M; Karnes RJ; Shariat S; Battaglia A; Everaerts W; Joniau S; Van Poppel H; Rajarubendra N; Gill IS; Larcher A; Mottrie A; Schmautz M; Heidenreich A; Kalz A; Osmonov D; Juenemann KP; Herlemann A; Gratzke C; Stief C; Montorsi F; Briganti A
    Eur Urol; 2019 Jan; 75(1):176-183. PubMed ID: 30301694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer.
    Ingrosso G; Mariucci C; Tenti MV; Bini V; Alì E; Saldi S; Palumbo I; Bellavita R; Aristei C
    Clin Transl Oncol; 2020 Dec; 22(12):2236-2243. PubMed ID: 32418156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
    Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
    Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial.
    Dai B; Zhang S; Wan FN; Wang HK; Zhang JY; Wang QF; Kong YY; Ma XJ; Mo M; Zhu Y; Qin XJ; Lin GW; Ye DW
    Eur Urol Oncol; 2022 Oct; 5(5):519-525. PubMed ID: 35780048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.